Hint mode is switched on Switch off
For swift navigation between sections

Replimune Group
LEI 549300AY704NEIRC4K64

PDF download

Choose all Reset all
Download Cancel
Organization name
Replimune Group, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

07/08/2026 Replimune Group Inc. (NASDAQ: REPL) Soars on Landmark FDA Approval for Skin Cancer Drug Tudriqev
31/07/2026 Replimune Group (NASDAQ: REPL) Soars on Citigroup Upgrade and Positive FDA Panel Vote for Melanoma Drug
30/07/2026 Replimune Group: And In The Accompanying Exhibit 99.1 Shall Not Be Incorporated By Reference Into Any Filing Of The Company, Whether Made Before Or After The Date Hereof, Regardless Of Any General Incorporation Language In Such Filing, Unless Expressly Incorporated By Specific Reference To Such Filing. The Information In This Item 7.01 And The Accompanying Exhibit 99.1 Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Otherwise Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended, Financial Statements And Exhibits
29/07/2026 Market Downturn: Replimune Group, Inc. (NASDAQ: REPL) Leads Stock Declines Amid Regulatory Setbacks and Earnings Misses
03/02/2026 Replimune Group: Of This Current Report On Form 8k, Including Exhibit 99.1, Shall Not Be Deemed “filed” For The Purposes Of Section 18 Of Thesecurities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under Thesecurities Act Of 1933, As Amended, Or Theexchange Act, Except As Expressly Stated By Specific Reference In Such Filing, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300AY704NEIRC4K64
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001737953
  • EIN
    82-2082553
Registration is required to get access.